Dogwood Therapeutics, Inc.

NASDAQ:DWTX

Biotechnology

Healthcare
$1.52 +2.22%

+$0.04 today

Market cap
$51.12M
Beta
1.76
P/E (TTM)
-0.2
EPS (TTM)
-$0.84
52W Low $1.28High $9.50

Volume 0.12M

Average 0.09M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$15.62M

FY 2025 · Annual

Investing Cash Flow

$0.00

FY 2025 · Annual

Financing Cash Flow

$7.28M

FY 2025 · Annual

-56.4% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(15.96M)(12.25M)(5.3M)(12.35M)(34.26M)
Depreciation & Amortization00012.18K2.06K
Deferred Income Tax000(503)221.1K
Stock-Based Compensation322.88K582.66K619.97K476.02K355.64K
Change in Working Capital(52.19K)197.38K(194.45K)(581.27K)(133K)
Accounts Receivables00000
Inventory00000
Accounts Payables270.01K219.3K(461.25K)219.89K(532.61K)
Other Working Capital(322.2K)(21.92K)266.81K(801.16K)399.6K
Other Non-Cash Items0003.65M18.19M
Operating Cash Flow(15.69M)(11.47M)(4.87M)(8.79M)(15.62M)
Capital Expenditures0(3)050
Acquisitions (Net)0003.76M0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0003.76M0
Debt Repayment00015.32M3M
Common Stock Issued04.49M1.16M1.38M4.34M
Common Stock Repurchased(295.17K)00(351)0
Dividends Paid00000
Other Financing Activities197.56K000(53.81K)
Financing Cash Flow(97.6K)4.49M1.16M16.7M7.28M
Effect of Forex Changes000(144.59K)10.64K
Net Change in Cash(15.79M)(6.98M)(3.71M)11.53M(8.32M)
Free Cash Flow(15.69M)(11.47M)(4.87M)(8.79M)(15.62M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$34.3M
+ D&A$2.1K
+ Stock-Based Comp$355.6K
+ Deferred Tax$221.1K
- Working Capital-$133.0K
+ Other Non-Cash$18.2M
= Operating Cash Flow-$15.6M
- Capex$0
= Free Cash Flow-$15.6M

Analysis

FY2025 free cash flow is -$15.6M. FCF conversion is 45.6% of net income. Operating cash flow was -$15.6M, with capex of $0. The largest bridge item is Other Non-Cash at $18.2M.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 7, 2025
8-KCurrent reportNov 6, 2025
DEF 14ADEF 14A filingOct 20, 2025
S-3/AS-3/A filingOct 16, 2025
DEFA14ADEFA14A filingOct 9, 2025

Does DWTX generate free cash flow?

Dogwood Therapeutics, Inc. (DWTX) generated -$15.62M of free cash flow in fiscal 2025.

How much operating cash flow does DWTX produce?

Operating cash flow was -$15.62M, before capital expenditures of $0.00.